Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001015

Norfloxacin for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Acide 1-éthyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylique

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C16H18FN3O3
Numéro CAS:
70458-96-7
Poids moléculaire :
319.33
Numéro MDL:
MFCD00079532
Code UNSPSC :
41116107
ID de substance PubChem :
329831219
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

norfloxacin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3

InChI

1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

Clé InChI

OGJPXUAPXNRGGI-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Norfloxacin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

La norfloxacine bloque la réplication de l′ADN en interférant avec un changement de structure - induit par l′ATP - de l′ADN complexé avec l′ADN-gyrase (topoisomérase).
Mode d′action : inhibe la réplication de l′ADN bactérien
Spectre antimicrobien : bactéries Gram-négatif ; moins efficace contre les bactéries Gram-positif

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

N1230000

Norfloxacin, European Pharmacopoeia (EP) Reference Standard

N1230010

Norfloxacin impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001301

Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard

1471506

Norfloxacin, United States Pharmacopeia (USP) Reference Standard

1471517

Norfloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1471550

Norfloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

1471583

Norfloxacin Related Compound H, United States Pharmacopeia (USP) Reference Standard

1471619

Norfloxacin Related Compound K, United States Pharmacopeia (USP) Reference Standard

PHR1614

Norfloxacin, Pharmaceutical Secondary Standard; Certified Reference Material

BP670

Norfloxacin, British Pharmacopoeia (BP) Reference Standard

PHR2233

Norfloxacin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ying-Jun Zhou et al.
FEMS microbiology letters, 355(2), 124-130 (2014-05-13)
The antimicrobial activity of one 3-hydroxypyridin-4-one (HPO) hexadentate (1) and three HPO hexadentate-based dendrimeric chelators (2-4) was evaluated. They were found to exhibit marked inhibitory effect on the growth of two Gram-positive bacteria and two Gram-negative bacteria. The combination treatment
L Miano et al.
European urology, 17 Suppl 1, 13-18 (1990-01-01)
A review of worldwide clinical trials with norfloxacin in the treatment of uncomplicated urinary tract infections (UTIs), as well as our personal experience with 215 assessable patients, is presented. Almost all patients received 400 mg b.i.d. for 3-15 days. Bacteriological
E J Goldstein
The American journal of medicine, 82(6B), 3-17 (1987-06-26)
Norfloxacin is an orally absorbed fluoroquinolone antibacterial with a fluorine at position 6 and a piperazine ring at position 7. These changes have resulted in a marked enhancement (compared with that of the older quinolones) of in vitro antibacterial activity.
Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.
D R Nalin
European journal of cancer & clinical oncology, 24 Suppl 1, S55-S61 (1988-01-01)
Nour El-Houda Jlili et al.
Journal of medical microbiology, 63(Pt 2), 195-202 (2013-11-07)
The prevalence of plasmid-mediated quinolone resistance genes [qnr, aac(6')-Ib-cr and qepA] was sought among Enterobacteriaceae strains obtained from the Children's Hospital of Tunis (Tunisia). Non-duplicate isolates (n = 278) with resistance to extended-spectrum cephalosporins and collected in 2003, 2007, 2008 and 2009
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique